Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3422927 | 0.80 | HSD11B1 (0.34) | HSD11B1 | |
| SCHEMBL5244705 | 0.75 | HSD11B1 (0.70) | HSD11B1ROCK2ALDH1A1SLC18A3 | |
| SCHEMBL5660198 | 0.75 | HSD11B1 (0.52) | HSD11B1ALDH1A1L3MBTL1USP2 | |
| SCHEMBL2986964 | 0.72 | HSD11B1 (1.00) | HSD11B1ROCK2ALDH1A1DDB1CRBN | |
| SCHEMBL16390739 | 0.67 | HSD11B1 (0.74) | HSD11B1ROCK2DDB1CRBN | |
| SCHEMBL4697081 | 0.67 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL4698786 | 0.67 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL5566934 | 0.67 | HSD11B1 (0.43) | HSD11B1ROCK2ALDH1A1 | |
| SCHEMBL13435191 | 0.66 | HSD11B1 (1.00) | HSD11B1ROCK2ALDH1A1DDB1CRBN | |
| SCHEMBL6654051 | 0.66 | HSD11B1 (0.56) | HSD11B1ROCK2ALDH1A1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | claimed |
| EP-1747198-B1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-04 | — | — | EP | claimed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | claimed |
| US-7687644-B2 | Adamantyl pyrrolidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-03-30 | — | — | US | disclosed |
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287743-A1 | Adamantyl Pyrrolidin-2-One Derivatives as 11-Beta Hydroxtsteroid Dehydrogenase Inhibitors | HSD11B1, HSD11B2, HSDL2 | HSD11B1 1/4885ROCK2 2350/4885ALDH1A1 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.